Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|February 14, 2019
Aigenpulse Achieves ISO Certification for AI Data Technology
Author(s)Pharmaceutical Technology Editors
Big data technology company, Aigenpulse, has been granted with International Organization for Standardization (ISO) 9001:2015 and ISO 27001:2013 certification.
Advertisement
Big data technology company, Aigenpulse, has been granted with International Organization for Standardization (ISO) 9001:2015 and ISO 27001:2013 certification, which are in recognition of product quality and management of information safely and securely, respectively.
“We are extremely proud of gaining certification to both ISO 9001 and ISO 27001 standards. These certifications underline our commitment to customers and our focus on quality, data security, and reliability,” said Tobias Kloepper, CEO of Aigenpulse, in a Feb. 5, 2019 press release. “As part of implementing a Quality Management System, we have automated all of our compliance processes, which have been designed to drive high quality performance and continuous improvement.”
Assessment of Aigenpulse’s offerings was performed independently by the British Assessment Bureau, which is a certification body. Through the ISO accreditation, Aigenpulse has strengthened its platform offering, which uses artificial intelligence (AI) and advanced machine learning technologies to help researchers analyse data.
“Customers, stakeholders and staff can be reassured that their information is being held and managed securely and that as a management team we take our accountability for protecting our systems and client data very seriously,” Kloepper added.
Source:
Advertisement
Related to this article
Richard Jaenisch explains what FDA's real-world use case database means for CMC and quality teams navigating NAMs.
Boyang Wang, Immortal Dragons, explains how FDA’s Expedited IND Pilot and research partners could speed serial steps to first-in-human trials compared to China’s 818 Decree.
This article examines how modern automation platforms create the digital foundation required for Pharma 4.0 by integrating manufacturing systems, centralized data management, Industrial Internet of Things connectivity, electronic batch production records, and AI-driven analytics.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Q&A: Patient-Centric Drug Development Should Start at Product Definition
2
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
3
PharmTech AI Pulse Check: AI Watermark Vulnerability
4
Clinical Trial Delays: FDA’s Expedited IND Pilot vs China’s 818 Decree
5